Quantum Biopharma (NASDAQ:QNTM) Stock Price Down 2.9% – Time to Sell?

Quantum Biopharma Ltd. (NASDAQ:QNTM) was down 2.9% during trading on Friday . The company traded as low as $3.23 and last traded at $3.31. Approximately 115,688 shares changed hands during trading, a decline of 11% from the average daily volume of 129,711 shares. The stock had previously closed at $3.41.

Analyst Upgrades and Downgrades

QNTM has been the subject of several research analyst reports. Weiss Ratings downgraded shares of Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th. Wall Street Zen downgraded Quantum Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Quantum Biopharma Trading Down 2.9%

The company has a 50-day moving average of $4.96 and a 200-day moving average of $4.80. The firm has a market capitalization of $12.64 million, a price-to-earnings ratio of -0.40 and a beta of 0.43.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Platform Technology Partners acquired a new position in shares of Quantum Biopharma in the 1st quarter valued at about $199,000. Jane Street Group LLC acquired a new stake in Quantum Biopharma during the fourth quarter worth about $80,000. Finally, Virtu Financial LLC bought a new position in Quantum Biopharma in the fourth quarter worth about $76,000. 1.24% of the stock is currently owned by institutional investors.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.